Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

A Review of Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy—Report of the ISPOR Risk–Benefit Management Working Group

3 references·12 citing·48 second hop

FromToDepth

this work references cited by second hop

References

1988An Assessment of Clinically Useful Measures of the Consequences of Treatment1,683 cited
1989Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis.341 cited
2002Reporting Number Needed to Treat and Absolute Risk Reduction in Randomized Controlled Trials239 cited

Cited by

2015Making Good Decisions in Healthcare with Multi-Criteria Decision Analysis: The Use, Current Research and Future Development of MCDA157 cited
2017Improving the quality of discrete-choice experiments in health: how can we assess validity and reliability?133 cited
2014Balancing benefit and risk of medicines: a systematic review and classification of available methodologies130 cited
2013The risks of risk aversion in drug regulation115 cited
2011A Comparison of Analytic Hierarchy Process and Conjoint Analysis Methods in Assessing Treatment Alternatives for Stroke Rehabilitation64 cited
2012A framework for organizing and selecting quantitative approaches for benefit-harm assessment58 cited
2015Use of the Analytic Hierarchy Process for Medication Decision-Making in Type 2 Diabetes49 cited
2014Multicriteria decision analysis in oncology48 cited
2014Clustering risk assessment method for shipbuilding industry27 cited
2013Assessing comparative effectiveness of new drugs before approval using prospective network meta-analyses18 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

2020Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)13 cited

2020A WHO tool for risk‐based decision making on blood safety interventions7 cited